Newly Hong Kong-listed biotech firm Insilico Medicine is expected to receive up to US$888 million from a French drug maker ...
The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...
A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...
Stocktwits on MSN
Genmab stock slips after discontinuing further development of cancer drug developed with BioNTech
The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...
The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...
Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...
WEST PALM BEACH, Fla (CBS12) — One of the pillars of modern medicine is the life-saving drugs that pharmaceutical companies spend years developing to cure and prevent diseases. But what if they could ...
Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback